Citigroup
CSTL icon

Citigroup’s Castle Biosciences CSTL Stock Holding History

Citigroup’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Buy
16,144
+12,117
+301% +$270K ﹤0.01% 4020
2026
Q1 		$98.9K Sell
4,027
-28,395
-88% -$930K ﹤0.01% 4289
2025
Q4 		$1.26M Buy
32,422
+28,172
+663% +$908K ﹤0.01% 2983
2025
Q3 		$96.8K Sell
4,250
-9,822
-70% -$200K ﹤0.01% 4278
2025
Q2 		$287K Sell
14,072
-48,629
-78% -$900K ﹤0.01% 3899
2025
Q1 		$1.26M Buy
62,701
+21,374
+52% +$529K ﹤0.01% 3089
2024
Q4 		$1.1M Buy
41,327
+15,748
+62% +$480K ﹤0.01% 3289
2024
Q3 		$730K Sell
25,579
-42,655
-63% -$1.09M ﹤0.01% 3494
2024
Q2 		$1.49M Buy
68,234
+61,580
+925% +$1.37M ﹤0.01% 2589
2024
Q1 		$147K Buy
6,654
+1,069
+19% +$23.3K ﹤0.01% 4142
2023
Q4 		$121K Buy
5,585
+2,855
+105% +$50.2K ﹤0.01% 4123
2023
Q3 		$46.1K Sell
2,730
-8,443
-76% -$148K ﹤0.01% 4166
2023
Q2 		$153K Buy
11,173
+8,427
+307% +$171K ﹤0.01% 4023
2023
Q1 		$62.4K Sell
2,746
-726
-21% -$17.7K ﹤0.01% 4198
2022
Q4 		$81.7K Sell
3,472
-83,501
-96% -$1.94M ﹤0.01% 4099
2022
Q3 		$2.27M Sell
86,973
-45,964
-35% -$1.29M ﹤0.01% 2056
2022
Q2 		$2.92M Buy
132,937
+124,294
+1,438% +$2.89M ﹤0.01% 1841
2022
Q1 		$388K Sell
8,643
-5,924
-41% -$245K ﹤0.01% 3672
2021
Q4 		$624K Sell
14,567
-1,061
-7% -$55.4K ﹤0.01% 3645
2021
Q3 		$1.04M Buy
15,628
+1,918
+14% +$135K ﹤0.01% 3052
2021
Q2 		$1M Buy
13,710
+11,993
+698% +$792K ﹤0.01% 3221
2021
Q1 		$118K Sell
1,717
-1,923
-53% -$145K ﹤0.01% 4281
2020
Q4 		$244K Buy
3,640
+1,778
+95% +$96.4K ﹤0.01% 4841
2020
Q3 		$96K Sell
1,862
-2,588
-58% -$115K ﹤0.01% 5150
2020
Q2 		$168K Buy
4,450
+665
+18% +$22.7K ﹤0.01% 5155
2020
Q1 		$113K Buy
3,785
+1,707
+82% +$51.5K ﹤0.01% 5246
2019
Q4 		$71K Buy
2,078
+1,915
+1,175% +$46.8K ﹤0.01% 6039
2019
Q3 		$3K Buy
+163
New +$3.61K ﹤0.01% 7446

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's CSTL Position: Q2 2026 in Review

Citigroup increased its Castle Biosciences (CSTL) stake by 301% in Q2 2026, buying an estimated $270K and bringing the position to 16,144 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #4020.

Citigroup first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $2.92M in Q2 2022. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Citigroup held 16,144 shares of Castle Biosciences worth $385K as of Q2 2026.
  • Citigroup bought 12,117 Castle Biosciences shares in Q2 2026, an estimated $270K.
  • Castle Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4020 holding.
  • Citigroup first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Citigroup's Castle Biosciences position peaked at $2.92M in Q2 2022.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.